Arch Dis Child 90:494-499 doi:10.1136/adc.2003.036590
  • Community child health, public health, and epidemiology

Bisphosphonate treatment of bone disease

  1. N J Shaw1,
  2. N J Bishop2
  1. 1Department of Endocrinology, Birmingham Children’s Hospital, UK
  2. 2Academic Unit of Child Health, Sheffield Children’s Hospital, University of Sheffield, UK
  1. Correspondence to:
    Dr N J Shaw
    Dept of Endocrinology, Birmingham Children’s Hospital, Steelhouse Lane, Birmingham B4 6NH, UK;
  • Accepted 15 November 2004


In 1997 a review article on bisphosphonates in this journal identified 24 published articles relating to children at that time.1 Since then there has been a considerable increase in their use in clinical paediatric practice and research with there being nearly a further one hundred articles published at the time of writing.


  • Competing interests: NJS and NJB have received funding from Novartis and the Arthritism & Rheumatism Council for studies of bisphosphonates in osteogenesis imperfecta. NJB has acted as an independent consultant for Proctor & Gamble.

Responses to this article